Evidence-based treatment strategies in idiopathic pulmonary fibrosis

Recently updated guidelines have provided revised recommendations, based on the GRADE criteria, for the diagnosis and pharmacological and non-pharmacological management of patients with idiopathic pulmonary fibrosis (IPF). Cochrane reviews are also a highly respected and reliable source of evidence-...

Full description

Bibliographic Details
Main Author: Jürgen Behr
Format: Article
Language:English
Published: European Respiratory Society 2013-06-01
Series:European Respiratory Review
Subjects:
Online Access:http://err.ersjournals.com/content/22/128/163.full.pdf+html
id doaj-63ddbd5f81144aaeb173e90904be48b3
record_format Article
spelling doaj-63ddbd5f81144aaeb173e90904be48b32020-11-24T21:44:52ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172013-06-012212816316810.1183/09059180.00001013Evidence-based treatment strategies in idiopathic pulmonary fibrosis Jürgen BehrRecently updated guidelines have provided revised recommendations, based on the GRADE criteria, for the diagnosis and pharmacological and non-pharmacological management of patients with idiopathic pulmonary fibrosis (IPF). Cochrane reviews are also a highly respected and reliable source of evidence-based information that identify and analyse all available data of overall treatment effects from appropriate studies. A recent update of one Cochrane review failed to identify any new evidence supporting the use of corticosteroids in IPF. Another review of data from 15 randomised controlled studies of non-steroid agents for the treatment of IPF identified two trials of interferon-γ-1b suitable for analysis. However, the pooled analysis revealed no treatment effect in terms of survival. A further meta-analysis of three phase III studies of pirfenidone treatment in IPF patients suggested a significant increase in progression-free survival. The interpretation of recent international and national European guideline updates and treatment recommendations, available clinical data from published and ongoing trials investigating potential pharmacological agents, and the individual patient's preferences, must be considered in the clinical management of this disease.http://err.ersjournals.com/content/22/128/163.full.pdf+htmlCochraneevidence basedguidelinesidiopathic pulmonary fibrosispirfenidonetreatment recommendations
collection DOAJ
language English
format Article
sources DOAJ
author Jürgen Behr
spellingShingle Jürgen Behr
Evidence-based treatment strategies in idiopathic pulmonary fibrosis
European Respiratory Review
Cochrane
evidence based
guidelines
idiopathic pulmonary fibrosis
pirfenidone
treatment recommendations
author_facet Jürgen Behr
author_sort Jürgen Behr
title Evidence-based treatment strategies in idiopathic pulmonary fibrosis
title_short Evidence-based treatment strategies in idiopathic pulmonary fibrosis
title_full Evidence-based treatment strategies in idiopathic pulmonary fibrosis
title_fullStr Evidence-based treatment strategies in idiopathic pulmonary fibrosis
title_full_unstemmed Evidence-based treatment strategies in idiopathic pulmonary fibrosis
title_sort evidence-based treatment strategies in idiopathic pulmonary fibrosis
publisher European Respiratory Society
series European Respiratory Review
issn 0905-9180
1600-0617
publishDate 2013-06-01
description Recently updated guidelines have provided revised recommendations, based on the GRADE criteria, for the diagnosis and pharmacological and non-pharmacological management of patients with idiopathic pulmonary fibrosis (IPF). Cochrane reviews are also a highly respected and reliable source of evidence-based information that identify and analyse all available data of overall treatment effects from appropriate studies. A recent update of one Cochrane review failed to identify any new evidence supporting the use of corticosteroids in IPF. Another review of data from 15 randomised controlled studies of non-steroid agents for the treatment of IPF identified two trials of interferon-γ-1b suitable for analysis. However, the pooled analysis revealed no treatment effect in terms of survival. A further meta-analysis of three phase III studies of pirfenidone treatment in IPF patients suggested a significant increase in progression-free survival. The interpretation of recent international and national European guideline updates and treatment recommendations, available clinical data from published and ongoing trials investigating potential pharmacological agents, and the individual patient's preferences, must be considered in the clinical management of this disease.
topic Cochrane
evidence based
guidelines
idiopathic pulmonary fibrosis
pirfenidone
treatment recommendations
url http://err.ersjournals.com/content/22/128/163.full.pdf+html
work_keys_str_mv AT jurgenbehr evidencebasedtreatmentstrategiesinidiopathicpulmonaryfibrosis
_version_ 1725908358982008832